Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US

First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.

Alps Pharma launches a new water soluble Isoquercetin

Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.

Aadi Bioscience launches Fyarro in the USA

Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa

Experts say extended day prescription refills for hypertension can be a game-changer

The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer

Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline

WHO establishes biomanufacturing training hub in South Korea

Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue